HeimNVO • NYSE
add
Novo Nordisk
38,02 $
Eftir lokun(0,053%)-0,020
38,00 $
Lokað: 12. mar., 19:59:38 GMT-4 · USD · NYSE · Lagalegir fyrirvarar
Við síðustu lokun
38,83 $
Dagbil
37,85 $ - 39,02 $
Árabil
35,85 $ - 82,57 $
Markaðsvirði
128,86 ma. USD
Meðalmagn
27,56 m.
V/H-hlutf.
10,66
A/V-hlutfall
4,89%
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (DKK) | des. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 79,14 ma. | -7,63% |
Rekstrarkostnaður | 29,73 ma. | 12,96% |
Nettótekjur | 26,89 ma. | -4,74% |
Hagnaðarhlutfall | 33,98 | 3,13% |
Hagnaður á hvern hlut | 6,04 | -4,73% |
EBITDA | 36,66 ma. | -23,44% |
Virkt skatthlutfall | 21,34% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (DKK) | des. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 26,96 ma. | 2,49% |
Heildareignir | 542,90 ma. | 16,60% |
Heildarskuldir | 348,86 ma. | 8,29% |
Eigið fé alls | 194,05 ma. | — |
Útistandandi hlutabréf | 4,44 ma. | — |
Eiginfjárgengi | 0,89 | — |
Arðsemi eigna | 16,70% | — |
Ávöxtun eigin fjár | 29,56% | — |
Peningaflæði
Breyting á handbæru fé
| (DKK) | des. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 26,89 ma. | -4,74% |
Handbært fé frá rekstri | 7,62 ma. | -38,06% |
Reiðufé frá fjárfestingum | -42,81 ma. | 53,07% |
Reiðufé frá fjármögnun | 29,47 ma. | -20,00% |
Breyting á handbæru fé | -5,62 ma. | 86,41% |
Frjálst peningaflæði | -34,95 ma. | -1.011,09% |
Um
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
Framkvæmdastjóri
Stofnsett
21. des. 1923
Höfuðstöðvar
Vefsvæði
Starfsfólk
69.150